Atomo Diagnostics (AT1) investor relations material

Executive summary

• Significant business momentum and commercial progress in early FY, driven by strategic deliverables, new product launches, and regulatory submissions.

• Board refresh completed with appointment of Patrick Cook as Chairman and CEO returning to full-time executive duties.

• Focus on expanding OEM supply agreements, particularly for Pascal and Flurry/Florey platforms.

• HIV Self-Test launched on Chemist Warehouse ecommerce in Australia and received international orders, including from USAID for Ukraine.

• Florey device presented at major US diagnostic conferences, targeting adoption as an accessory for existing tests.

Financial highlights

• Unaudited quarterly revenue just under $700,000, mainly from HIV and OEM Pascal sales, and development fees.

• Operating costs for the quarter were $1.3 million, with CRC-P income of ~$200,000 recognized for Active Syphilis development.

• Cash receipts totaled just under $2.3 million, including $1.3 million from capital raising and $165,000 from a CRC-P grant.

• Ended Q1 debt-free with $3.39 million cash on hand; R&D tax rebate of ~$875,000 expected post quarter-end.

• Net cash used in operating activities was $(1.13) million for the quarter.

Outlook and guidance

• Expectation of material increase in Pascal sales as Faber DX supply ramps up and new customers join, pending CLIA waiver.

• Strategic priorities include expanding distributor network for HIV Self-Testing and growing OEM customer base for Pascal and Florey.

• Plans to expand the finished test portfolio on Pascal, including Active Syphilis and Blood pregnancy tests.

• Ongoing operational scale-up for AtomoRapid Pascal and syphilis test manufacturing.